Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Cited In for PubMed (Select 19047117)

1.

The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.

Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, Schiemann WP.

Neoplasia. 2015 Jan;17(1):124-33. doi: 10.1016/j.neo.2014.11.009.

2.

Emerging targeted combinations in the management of breast cancer.

Lee RJ, Armstrong AC, Wardley AM.

Breast Cancer (Dove Med Press). 2013 Aug 13;5:61-72. doi: 10.2147/BCTT.S26771. eCollection 2013. Review.

3.

Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.

Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, Schiemann WP.

Breast Cancer Res. 2014 Mar 11;16(2):R24. doi: 10.1186/bcr3623.

4.

Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Pories SE, Wulf GM.

Breast Cancer (Dove Med Press). 2010 Jun 21;2:37-44. Review.

5.

MicroRNAs and triple negative breast cancer.

D'Ippolito E, Iorio MV.

Int J Mol Sci. 2013 Nov 11;14(11):22202-20. doi: 10.3390/ijms141122202. Review.

6.

Biomarkers for Basal-like Breast Cancer.

Choo JR, Nielsen TO.

Cancers (Basel). 2010 May 28;2(2):1040-65. doi: 10.3390/cancers2021040.

7.

TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion.

Giricz O, Calvo V, Peterson EA, Abouzeid CM, Kenny PA.

Int J Cancer. 2013 Dec 1;133(11):2587-95. doi: 10.1002/ijc.28295. Epub 2013 Jun 21.

8.

Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP, Carlin CR.

J Biol Chem. 2013 Jun 21;288(25):17954-67. doi: 10.1074/jbc.M113.475277. Epub 2013 May 7.

9.

The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

Kieran MW, Kalluri R, Cho YJ.

Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a006593. doi: 10.1101/cshperspect.a006593. Review.

10.

Role of epidermal growth factor receptor in breast cancer.

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT.

Breast Cancer Res Treat. 2012 Nov;136(2):331-45. doi: 10.1007/s10549-012-2289-9. Epub 2012 Oct 17. Review.

11.

Breast cancer chemoprevention: old and new approaches.

Cazzaniga M, Bonanni B.

J Biomed Biotechnol. 2012;2012:985620. doi: 10.1155/2012/985620. Epub 2012 Jul 17. Review.

12.

Bevacizumab and breast cancer: what does the future hold?

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K.

Future Oncol. 2012 Apr;8(4):403-14. doi: 10.2217/fon.12.22. Review.

13.

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.

Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung TT, Fan ST, Poon RT.

Invest New Drugs. 2012 Dec;30(6):2384-90. doi: 10.1007/s10637-012-9808-8. Epub 2012 Mar 9.

14.

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.

Jacot W, Lopez-Crapez E, Thezenas S, Senal R, Fina F, Bibeau F, Romieu G, Lamy PJ.

Breast Cancer Res. 2011;13(6):R133. doi: 10.1186/bcr3079. Epub 2011 Dec 22.

15.

αB-crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells.

Ruan Q, Han S, Jiang WG, Boulton ME, Chen ZJ, Law BK, Cai J.

Mol Cancer Res. 2011 Dec;9(12):1632-43. doi: 10.1158/1541-7786.MCR-11-0327. Epub 2011 Oct 7.

16.

Recent advances in anti-angiogenic therapy of cancer.

Samant RS, Shevde LA.

Oncotarget. 2011 Mar;2(3):122-34. Review.

17.

Antiangiogenic therapy for breast cancer.

Nielsen DL, Andersson M, Andersen JL, Kamby C.

Breast Cancer Res. 2010;12(5):209. doi: 10.1186/bcr2642. Epub 2010 Sep 29. Review.

18.

Present and future evolution of advanced breast cancer therapy.

Alvarez RH.

Breast Cancer Res. 2010;12 Suppl 2:S1. doi: 10.1186/bcr2572. Epub 2010 Oct 22. Review.

19.

Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.

Toft DJ, Cryns VL.

Mol Endocrinol. 2011 Feb;25(2):199-211. doi: 10.1210/me.2010-0164. Epub 2010 Sep 22. Review.

20.

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, Philip PA, Picus J, Yong WP, Horvath L, Van Hazel G, Erlichman CE, Holen KD.

J Clin Oncol. 2010 Jul 20;28(21):3491-7. doi: 10.1200/JCO.2010.28.4075. Epub 2010 Jun 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk